Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Algernon Pharmaceuticals Announces 50% Enrollment of its Ife

<< Previous

Bullboard Posts

Next >>

Comment by Danorrnon May 11, 2021 11:18am

137 Views

Post# 33173551

RE:RE:Algernon Pharmaceuticals Announces 50% Enrollment of its Ife

I'd like to know who, in their right mind, thinks that putting out these sh!tty NRs is a good thing? Are they intentionally trying to lower the share price? Dumbasse$.

<< Previous

Bullboard Posts

Next >>

Sony shuts down Firewalk Studios after ‘Concord’ crash